REGENXBIO Inc

24 ago 2026, 19:51 UTC

Regenxbio Inc shares are lower following the FDA's clinical hold on RGX-121 due to MRI findings, with Bank of America maintaining a $15 price target.

21 ago 2026, 19:26 UTC

Regenxbio Inc shares are declining today amid notable volatility, pulling back significantly from an earlier peak during the session. No specific news was identified.

20 ago 2026, 20:02 UTC

Regenxbio Inc. shares are lower as biotechnology stocks face pressure today, with no specific news identified to explain the decline.

19 ago 2026, 22:06 UTC

Regenxbio Inc shares are higher in after-market trading, continuing a positive trend since Wednesday's close and remaining above their 20-day moving average.

18 ago 2026, 19:46 UTC

Regenxbio Inc's shares are lower today amid rising Treasury yields and inflation concerns. The stock remains above its 20-day moving average.

17 ago 2026, 20:06 UTC

Regenxbio Inc shares are higher today, reflecting strong market performance. The stock remains near its one-month high and above its 20-day moving average.

14 ago 2026, 19:36 UTC

Regenxbio Inc shares are higher during Friday's session, advancing despite a reported decline in retail sales for July.

13 ago 2026, 21:31 UTC

Regenxbio Inc shares are lower in after-market hours, pulling back from an earlier session high. No specific news was identified to explain the decline.

12 ago 2026, 19:41 UTC

Regenxbio Inc shares are higher today amid positive market sentiment following a modest increase in the core Consumer Price Index.

11 ago 2026, 19:11 UTC

Biotechnology stocks are advancing today, contributing to Regenxbio Inc's higher price movement. The stock pulled back earlier but remains in positive territory overall.

10 ago 2026, 19:46 UTC

Regenxbio Inc shares are lower today after H.C. Wainwright cut its price target to $23.00, despite a strong Q2 earnings report.

7 ago 2026, 20:06 UTC

Barclays downgraded Regenxbio Inc to Equal-Weight from Overweight, maintaining a $12 price target. Shares are trading lower amid concerns about growth prospects.

6 ago 2026, 23:31 UTC

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

5 ago 2026, 19:26 UTC

Regenxbio Inc shares are higher during Wednesday's session, despite intraday volatility. Broader market sentiment is influenced by a recent decline in crude oil prices.

4 ago 2026, 19:56 UTC

Regenxbio Inc shares are higher, reflecting market strength amid a decline in crude oil prices that eased inflation concerns. No specific company news was identified.

31 lug 2026, 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30 lug 2026, 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29 lug 2026, 19:56 UTC

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28 lug 2026, 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27 lug 2026, 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24 lug 2026, 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22 lug 2026, 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21 lug 2026, 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20 lug 2026, 19:31 UTC

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.